AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33994160 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions including mother-baby psychotherapy, educational or guidance programs, care for premature infants, infant massage, and home visits.
Number of subjects: 41
Study 32551827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga classes (25 minutes, twice weekly for 12 weeks)
Number of subjects: 174
Study 32551827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 174
Study 35585696 — intervention group
Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (oral)
Number of subjects: 1781
Study 35585696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1781
Study 32341237 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc (150 mg/d) plus pantoprazole (40 mg/d)
Number of subjects: 210
Study 32341237 — intervention group
Group type: COMPARATOR
Intervention: Rebamipide (300 mg/d) plus pantoprazole (40 mg/d)
Number of subjects: 210
Study 32312302 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care + e-device for recording step count (fit bit)
Number of subjects: 120
Study 32312302 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care + daily motivational e-messages to maintain the log book
Number of subjects: 120
Study 32312302 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care + e-device for measuring step count (fit bit) + daily motivational e-messages
Number of subjects: 120
Study 32312302 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical care (Control group)
Number of subjects: 120
Study 36378671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aleglitazar (PPAR-α/γ agonist)
Number of subjects: 7226
Study 36378671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7226
Study 32233350 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 22
Study 36374352 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed titanium surgical guide
Number of subjects: 38
Study 36374352 — intervention group
Group type: COMPARATOR
Intervention: Free-hand extractions
Number of subjects: 38
Study 33718273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ae. aegypti pools screened for arboviruses by RT‐PCR
Number of subjects: 769541
Study 33718273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cx. quinquefasciatus pools screened for arboviruses by RT‐PCR
Number of subjects: 769541
Study 32432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger of stereotype threat (A): residents read abstracts reporting that women had worse laparoscopic skill performance than men.
Number of subjects: 131
Study 32432669 — intervention group
Group type: COMPARATOR
Intervention: Protection against stereotype threat (B): residents read abstracts with no difference in performance.
Number of subjects: 131
Study 32432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐male gender bias perception among men.
Number of subjects: 131
Study 32432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro‐male gender bias perception among women.
Number of subjects: 131
Study 32432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat activation response.
Number of subjects: 131
Study 32432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotype threat activation and FLS score among women.
Number of subjects: 131
Study 36068298 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamines (specific dosage and duration not mentioned)
Number of subjects: 0
Study 36068298 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 34409800 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal endoscope‐assisted subgingival scaling
Number of subjects: 13
Study 34409800 — intervention group
Group type: COMPARATOR
Intervention: Traditional subgingival scaling (control group)
Number of subjects: 13
Study 32645137 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐15 levels in the highest quartile (≥358 pg/mL)
Number of subjects: 416
Study 32645137 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF‐15 levels across quartiles
Number of subjects: 416
Study 32645137 — intervention group
Group type: COMPARATOR
Intervention: GDF‐15 levels predicted by SNPs
Number of subjects: 416
Study 33805883 — intervention group
Group type: EXPERIMENTAL
Intervention: β-Hydroxy-β-Methylbutyrate (7.5 g) and L-Arginine α-Ketoglutarate (10 g) supplementation
Number of subjects: 40
Study 33805883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 32315057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (5 mg in 100 mL saline solution)
Number of subjects: 223
Study 32315057 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 223
Study 32315057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Number of subjects: 223
Study 35578356 — intervention group
Group type: EXPERIMENTAL
Intervention: TOWER intervention (patient-facing opioid management app, progress note template, PCP training)
Number of subjects: 40
Study 35578356 — intervention group
Group type: EXPERIMENTAL
Intervention: TOWER intervention
Number of subjects: 40
Study 35578356 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 40
Study 33707980 — intervention group
Group type: COMPARATOR
Intervention: music‐based training group (MBT)
Number of subjects: 30
Study 33707980 — intervention group
Group type: COMPARATOR
Intervention: mindfulness‐based mental training group (MBMT)
Number of subjects: 30
Study 33707980 — intervention group
Group type: EXPERIMENTAL
Intervention: control group (CG)
Number of subjects: 30
Study 32369036 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Behavioral Therapy (VR-CBT)
Number of subjects: 116
Study 32369036 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 116
Study 35773175 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 500
Study 33894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevuparin (18 mg/kg per day)
Number of subjects: 144
Study 33894169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl, 0.9% solution)
Number of subjects: 144
Study 33894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevuparin
Number of subjects: 144
Study 33894169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 34078482 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe-biofortified pearl millet
Number of subjects: 130
Study 34078482 — intervention group
Group type: COMPARATOR
Intervention: Conventional pearl millet
Number of subjects: 130
Study 33738495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m2 IV Q3W, prednisone, G-CSF)
Number of subjects: 222
Study 35930378 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Planning
Number of subjects: 221
Study 35930378 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic Effort Action Planning (REAP)
Number of subjects: 221
Study 35930378 — intervention group
Group type: COMPARATOR
Intervention: Information
Number of subjects: 221
Study 32356185 — intervention group
Group type: EXPERIMENTAL
Intervention: sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin
Number of subjects: 104
Study 32356185 — intervention group
Group type: EXPERIMENTAL
Intervention: sofosbuvir/simeprevir/daclatasvir + ribavirin
Number of subjects: 104
Study 32356185 — intervention group
Group type: COMPARATOR
Intervention: Control group (SOF/DCV-based therapy)
Number of subjects: 104
Study 32115652 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP, n=20)
Number of subjects: 63
Study 32115652 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Condition (ACC, n=20)
Number of subjects: 63
Study 32115652 — intervention group
Group type: COMPARATOR
Intervention: Passive Waiting Group (PW, n=23)
Number of subjects: 63
Study 34236460 — intervention group
Group type: EXPERIMENTAL
Intervention: Refixation of the SSC-tendon
Number of subjects: 50
Study 34236460 — intervention group
Group type: COMPARATOR
Intervention: Non-refixation of the SSC-tendon
Number of subjects: 50
Study 34381155 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/24 h for 7 days
Number of subjects: 305
Study 34381155 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg/12 h for 7 days
Number of subjects: 305
Study 34381155 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 305
Study 32412629 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 197
Study 32412629 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 197
Study 32238020 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy with uterine manipulator (UM) guidance
Number of subjects: 0
Study 32238020 — intervention group
Group type: COMPARATOR
Intervention: Conventional hysterectomy (control group)
Number of subjects: 0
Study 32026839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure ice (500g)
Number of subjects: 16
Study 32026839 — intervention group
Group type: EXPERIMENTAL
Intervention: Wetted ice (500g of ice in 50ml of water)
Number of subjects: 16
Study 32026839 — intervention group
Group type: COMPARATOR
Intervention: Watered ice (500g of ice in 500ml of water)
Number of subjects: 16
Study 35305111 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate (70 mg/kg)
Number of subjects: 30
Study 35305111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35305111 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Number of subjects: 30
Study 32684362 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 g/day CLA
Number of subjects: 66
Study 32684362 — intervention group
Group type: COMPARATOR
Intervention: 3.2 g/day placebo (sunflower oil)
Number of subjects: 66
Study 36330564 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual and Healthy Nordic diets with Usual Sodium intake
Number of subjects: 106
Study 36330564 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual and Healthy Nordic diets with Reduced Sodium intake
Number of subjects: 106
Study 36330564 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt ingestion or changes in diet
Number of subjects: 106
Study 36330564 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 106
Study 34412750 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiedu Limai decoction
Number of subjects: 100
Study 33079968 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic net model for predicting overdose
Number of subjects: 5293880
Study 33079968 — intervention group
Group type: COMPARATOR
Intervention: Simpler models (few predictors)
Number of subjects: 5293880
Study 33079968 — intervention group
Group type: COMPARATOR
Intervention: Baseline predictors only
Number of subjects: 5293880
Study 34794261 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel dressing+vaseline gauze
Number of subjects: 168
Study 34794261 — intervention group
Group type: COMPARATOR
Intervention: Vaseline gauze only
Number of subjects: 168
Study 32810194 — intervention group
Group type: EXPERIMENTAL
Intervention: BBOFT+ intervention
Number of subjects: 1995
Study 35088760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA) at acupuncture points LI4 and ST36, performed for one hour twice daily for one month.
Number of subjects: 42
Study 35088760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 42
Study 35088760 — intervention group
Group type: COMPARATOR
Intervention: Sham‐TEA
Number of subjects: 42
Study 35088760 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TEA and sham‐TEA
Number of subjects: 42
Study 35088760 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 42
Study 34608724 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact profile (n=150; 57.9%)
Number of subjects: 259
Study 34608724 — intervention group
Group type: EXPERIMENTAL
Intervention: High-impact profile (n=88; 34.0%)
Number of subjects: 259
Study 34608724 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-impact profile (n=21; 8.1%)
Number of subjects: 259
Study 33359382 — intervention group
Group type: EXPERIMENTAL
Intervention: Group educational intervention
Number of subjects: 149
Study 33359382 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 149
Study 33359382 — intervention group
Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 149
Study 33359382 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 149
Study 35858874 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF-ART
Number of subjects: 3543
Study 35858874 — intervention group
Group type: COMPARATOR
Intervention: ZDV-ART
Number of subjects: 3543
Study 35858874 — intervention group
Group type: COMPARATOR
Intervention: ZDV Alone
Number of subjects: 3543
Study 33782365 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-start T&E regimen (2W interval adjustments)
Number of subjects: 271
Study 33782365 — intervention group
Group type: COMPARATOR
Intervention: Late-start T&E regimen (8W intervals until W48 then 2W interval adjustments)
Number of subjects: 271
Study 32151992 — intervention group
Group type: EXPERIMENTAL
Intervention: Body positive captions on average images
Number of subjects: 384
Study 32151992 — intervention group
Group type: EXPERIMENTAL
Intervention: Body positive captions on thin images
Number of subjects: 384
Study 32151992 — intervention group
Group type: COMPARATOR
Intervention: Average images
Number of subjects: 384
Study 32151992 — intervention group
Group type: COMPARATOR
Intervention: Thin images
Number of subjects: 384
Study 33341402 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (n = 87)
Number of subjects: 173
Study 33341402 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep (n = 86)
Number of subjects: 173
Study 32728650 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Handbook
Number of subjects: 0
Study 32728650 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Handbook Plus
Number of subjects: 0
Study 32728650 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35343321 — intervention group
Group type: COMPARATOR
Intervention: 0% gradient (0CON)
Number of subjects: 25
Study 35343321 — intervention group
Group type: COMPARATOR
Intervention: 2% gradient (2CON)
Number of subjects: 25
Study 35343321 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% at isoefficiency speed (2IES)
Number of subjects: 25
Study 33712920 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic and resistance group exercise sessions (3 times per week)
Number of subjects: 54
Study 33712920 — intervention group
Group type: COMPARATOR
Intervention: Gentle exercise program (1 time per week)
Number of subjects: 54
Study 33106226 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Health Literacy Assessment (DHLA)
Number of subjects: 1588
Study 33106226 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 1588
Study 36056413 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening the Conversation (OC) intervention
Number of subjects: 100
Study 36056413 — intervention group
Group type: COMPARATOR
Intervention: Side by Side (active control)
Number of subjects: 100
Study 32716114 — intervention group
Group type: EXPERIMENTAL
Intervention: tivantinib (120 mg bid)
Number of subjects: 195
Study 32716114 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 195
Study 36176963 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 98
Study 36176963 — intervention group
Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 98
Study 33689694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain coping skills training, arthritis education, and usual care
Number of subjects: 384
Study 36078628 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) + Isometrics
Number of subjects: 60
Study 33475735 — intervention group
Group type: EXPERIMENTAL
Intervention: Svo2-guided transfusion
Number of subjects: 100
Study 33475735 — intervention group
Group type: COMPARATOR
Intervention: Control (standard transfusion)
Number of subjects: 100
Study 33348621 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing A2 β-casein only
Number of subjects: 33
Study 33348621 — intervention group
Group type: COMPARATOR
Intervention: Conventional milk
Number of subjects: 33
Study 32063213 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality peritoneal dialysis
Number of subjects: 0
Study 32063213 — intervention group
Group type: COMPARATOR
Intervention: Urea clearance
Number of subjects: 0
Study 32241299 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, systematic integration of oncology and specialized palliative care in intervention hospitals.
Number of subjects: 680
Study 32241299 — intervention group
Group type: COMPARATOR
Intervention: Conventional care in control hospitals.
Number of subjects: 680
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib 10 mg
Number of subjects: 48
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib 20 mg
Number of subjects: 48
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib 30 mg
Number of subjects: 48
Study 36281667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib 20 mg (multiple ascending dose)
Number of subjects: 48
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib 30 mg (multiple ascending dose)
Number of subjects: 48
Study 36281667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple ascending dose)
Number of subjects: 48
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib 30 mg (bioavailability)
Number of subjects: 48
Study 36281667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icapamespib (oral solution)
Number of subjects: 48
Study 33905405 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.08 mg/kg)
Number of subjects: 86
Study 33905405 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 86
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.03 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.1 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.3 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 1 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 2 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 4 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 6 mg
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.3 mg once daily for 14 days
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 1 mg once daily for 28 days
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 0.3 mg once daily for 28 days
Number of subjects: 99
Study 32969202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iberdomide 1 mg once daily for 7 days with a 7-day washout, then once daily for 7 more days
Number of subjects: 99
Study 32093499 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-based compact system
Number of subjects: 17
Study 32093499 — intervention group
Group type: COMPARATOR
Intervention: Clinical rating scales (BARS, SAS, MDS‐UPDRS III)
Number of subjects: 17
Study 37622634 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized raloxifene 45 mg
Number of subjects: 49
Study 37622634 — intervention group
Group type: COMPARATOR
Intervention: Conventional raloxifene 60 mg
Number of subjects: 49
Study 37622634 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 49
Study 33873267 — intervention group
Group type: EXPERIMENTAL
Intervention: HPLF + ACT (5-min cycling every 30 min)
Number of subjects: 24
Study 33873267 — intervention group
Group type: EXPERIMENTAL
Intervention: WEST + ACT
Number of subjects: 24
Study 33873267 — intervention group
Group type: EXPERIMENTAL
Intervention: PA breaks
Number of subjects: 24
Study 33873267 — intervention group
Group type: COMPARATOR
Intervention: HPLF + SIT
Number of subjects: 24
Study 32798787 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 190
Study 35379307 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted consultant pharmacist intervention to deprescribe opioids and BZDs (n = 8 practices)
Number of subjects: 1962
Study 35379307 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 7 practices)
Number of subjects: 1962
Study 35379307 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1962
Study 32674743 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of cruciferous vegetables (>44.6 g/d)
Number of subjects: 684
Study 32674743 — intervention group
Group type: COMPARATOR
Intervention: Lower intake of cruciferous vegetables (<15.0 g/d)
Number of subjects: 684
Study 32674743 — intervention group
Group type: COMPARATOR
Intervention: Total vegetable intake and other vegetable types
Number of subjects: 684
Study 35167360 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loving Kindness Meditation (LKM) group
Number of subjects: 979
Study 35167360 — intervention group
Group type: COMPARATOR
Intervention: Deferred LKM group (control)
Number of subjects: 979
Study 35339350 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS 10Hz, 2400 pulses
Number of subjects: 20
Study 35339350 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS 20Hz, 3600 pulses
Number of subjects: 20
Study 35339350 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 33040562 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 56
Study 33040562 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 56